Tech Company Financing Transactions
Amplifier Therapeutics Funding Round
On 10/17/2023, Amplifier Therapeutics landed $33.3 million in Series A funding from Cambrian Biopharma, Future Ventures and RA Capital Management.
Transaction Overview
Company Name
Announced On
10/17/2023
Transaction Type
Venture Equity
Amount
$33,300,000
Round
Series A
Proceeds Purpose
The Phase 1B trial is an 8-week, double-blind, randomized placebo-controlled study in prediabetic, overweight or obese subjects, being conducted in the European Union. The study will focus primarily on the safety and pharmacokinetics of ATX-304 and also will include exploratory outcomes measuring its effect on metabolic parameters and muscle.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8911 North Capital of Texas Highway 4200
Austin, TX 78759
USA
Austin, TX 78759
USA
Phone
Undisclosed
Website
Email Address
Overview
Our company Parhelia Bio provides a simple, efficient, and affordable solution to tissue auto-staining and automation for research, diagnostic, and pathology labs. We (the founders of Parhelia Bio) met at Stanford while doing our postdocs in the Nolan lab. Together we collaborated on the development of CODEX ultra--multiplexed staining technology and co-founded Akoya Biosciences (NASDAQ:AKYA) to commercialize CODEX and related methods. CODEX and Opal (later acquired by Akoya from Perkin Elmer) are now considered key technologies in the rapidly growing field of spatial biology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Mike Stadnisky
Chief Executive Officer
Nikolay Samusik
Co-Founder
Yury Goltsev
Co-Founder
Garry Nolan
Browse more venture capital transactions:
Prev: 10/17/2023: Anonybit venture capital transaction
Next: 10/17/2023: Modifi Bio venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs